🚀 VC round data is live in beta, check it out!
Celldex Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Celldex Therapeutics and similar public comparables like Stoke Therapeutics, Hugel, Cheezheng Tibetan Medicine, Bora Pharmaceuticals and more.
Celldex Therapeutics Overview
About Celldex Therapeutics
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Founded
1983
HQ
Employees
198
Website
Sectors
Financials (LTM)
EV
$1B
Celldex Therapeutics Financials
Celldex Therapeutics reported last 12-month revenue of $2M and negative EBITDA of ($288M).
In the same LTM period, Celldex Therapeutics generated $2M in gross profit, ($288M) in EBITDA losses, and had net loss of ($274M).
Revenue (LTM)
Celldex Therapeutics P&L
In the most recent fiscal year, Celldex Therapeutics reported revenue of $2M and EBITDA of ($273M).
Celldex Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($288M) | XXX | ($273M) | XXX | XXX | XXX |
| EBITDA Margin | (16215%) | XXX | (17673%) | XXX | XXX | XXX |
| EBIT Margin | (16887%) | XXX | (18599%) | XXX | XXX | XXX |
| Net Profit | ($274M) | XXX | ($259M) | XXX | XXX | XXX |
| Net Margin | (15457%) | XXX | (16748%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Celldex Therapeutics Stock Performance
Celldex Therapeutics has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Celldex Therapeutics' stock price is $29.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $-3.89 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCelldex Therapeutics Valuation Multiples
Celldex Therapeutics trades at 816.5x EV/Revenue multiple, and (5.0x) EV/EBITDA.
EV / Revenue (LTM)
Celldex Therapeutics Financial Valuation Multiples
As of March 18, 2026, Celldex Therapeutics has market cap of $2B and EV of $1B.
Equity research analysts estimate Celldex Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Celldex Therapeutics has a P/E ratio of (7.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 816.5x | XXX | 937.7x | XXX | XXX | XXX |
| EV/EBITDA | (5.0x) | XXX | (5.3x) | XXX | XXX | XXX |
| EV/EBIT | (4.8x) | XXX | (5.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 816.5x | XXX | — | XXX | XXX | XXX |
| P/E | (7.2x) | XXX | (7.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (6.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Celldex Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Celldex Therapeutics Margins & Growth Rates
Celldex Therapeutics' revenue in the last 12 month grew by 163%.
Celldex Therapeutics' revenue per employee in the last FY averaged $0.0M.
Celldex Therapeutics' rule of 40 is (16052%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Celldex Therapeutics' rule of X is (15807%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Celldex Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 163% | XXX | 70% | XXX | XXX | XXX |
| EBITDA Margin | (16215%) | XXX | (17673%) | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 25% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (16052%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (15807%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2019% | XXX | 2837% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14524% | XXX | 15862% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 18700% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Celldex Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Stoke Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Hugel | XXX | XXX | XXX | XXX | XXX | XXX |
| Cheezheng Tibetan Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Bora Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Nektar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celldex Therapeutics M&A Activity
Celldex Therapeutics acquired XXX companies to date.
Last acquisition by Celldex Therapeutics was on XXXXXXXX, XXXXX. Celldex Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Celldex Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCelldex Therapeutics Investment Activity
Celldex Therapeutics invested in XXX companies to date.
Celldex Therapeutics made its latest investment on XXXXXXXX, XXXXX. Celldex Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Celldex Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Celldex Therapeutics
| When was Celldex Therapeutics founded? | Celldex Therapeutics was founded in 1983. |
| Where is Celldex Therapeutics headquartered? | Celldex Therapeutics is headquartered in United States. |
| How many employees does Celldex Therapeutics have? | As of today, Celldex Therapeutics has over 198 employees. |
| Who is the CEO of Celldex Therapeutics? | Celldex Therapeutics' CEO is Anthony S. Marucci. |
| Is Celldex Therapeutics publicly listed? | Yes, Celldex Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Celldex Therapeutics? | Celldex Therapeutics trades under CLDX ticker. |
| When did Celldex Therapeutics go public? | Celldex Therapeutics went public in 1986. |
| Who are competitors of Celldex Therapeutics? | Celldex Therapeutics main competitors are Stoke Therapeutics, Hugel, Cheezheng Tibetan Medicine, Bora Pharmaceuticals. |
| What is the current market cap of Celldex Therapeutics? | Celldex Therapeutics' current market cap is $2B. |
| What is the current revenue of Celldex Therapeutics? | Celldex Therapeutics' last 12 months revenue is $2M. |
| What is the current revenue growth of Celldex Therapeutics? | Celldex Therapeutics revenue growth (NTM/LTM) is 163%. |
| What is the current EV/Revenue multiple of Celldex Therapeutics? | Current revenue multiple of Celldex Therapeutics is 816.5x. |
| Is Celldex Therapeutics profitable? | No, Celldex Therapeutics is not profitable. |
| What is the current EBITDA of Celldex Therapeutics? | Celldex Therapeutics has negative EBITDA and is not profitable. |
| What is Celldex Therapeutics' EBITDA margin? | Celldex Therapeutics' last 12 months EBITDA margin is (16215%). |
| What is the current EV/EBITDA multiple of Celldex Therapeutics? | Current EBITDA multiple of Celldex Therapeutics is (5.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.